Search

Ionis Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

56.55 3.91

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

53.84

Massimo

55.23

Metriche Chiave

By Trading Economics

Entrata

-22M

-115M

Vendite

22M

268M

EPS

-0.7

Margine di Profitto

-42.787

Dipendenti

1,480

EBITDA

-37M

-105M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+66.32% upside

Dividendi

By Acuity

Utili prossimi

28 ott 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-193M

9.1B

Apertura precedente

52.64

Chiusura precedente

56.55

Notizie sul Sentiment di mercato

By Acuity

100%

0%

329 / 340 Classifica in Healthcare

Ionis Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 ago 2026, 20:03 UTC

Macro Event

Ionis Pharmaceuticals Inc shares are higher, supported by high trading volume, though they remain below their 20-day moving average and near a one-month low.

5 ago 2026, 23:56 UTC

Ionis Pharmaceuticals shares are lower in after-market hours, influenced by a disappointing ADP employment report revealing only 44,000 private sector jobs added in July.

4 ago 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, having reached a session low earlier. No specific news was identified to explain the movement.

3 ago 2026, 20:51 UTC

Ionis Pharmaceuticals Inc. shares are trading roughly flat in after-market hours, maintaining a cumulative return of 0.02% since Monday's close.

1 ago 2026, 00:06 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, recovering from recent declines amid broader market gains, including a rise in the Nikkei 225 Index.

31 lug 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, supported by a notable advance in the Biotechnology sub-sector. No specific news was identified.

30 lug 2026, 23:46 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours, though no specific news explains the movement amid mixed Asian equity performance and geopolitical concerns.

29 lug 2026, 23:51 UTC

Ionis Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of four consecutive sessions below its 20-day moving average.

28 lug 2026, 18:03 UTC

News

Ionis Pharmaceuticals shares are lower amid an investigation by Bronstein, Gewirtz & Grossman and disappointing earnings forecasts projecting a loss of $1.07 per share.

27 lug 2026, 20:07 UTC

News
Social Media

Ionis Pharmaceuticals shares are lower amid an investigation into potential claims following the company's disclosure about its failed Phase-3 trial.

25 lug 2026, 00:02 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, diverging from recent gains. No specific news was identified to explain the decline.

24 lug 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, following a broader market decline driven by disappointing earnings from major companies and falling crude oil prices.

23 lug 2026, 20:03 UTC

Ionis Pharmaceuticals Inc shares are higher during Thursday's session, continuing a notable increase since Wednesday. Trading volume is unusually high today.

22 lug 2026, 22:26 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours. Broader market conditions reflect ongoing geopolitical tensions and rising crude oil prices.

21 lug 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The broader market is rebounding.

20 lug 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market trading, recovering from earlier lows after three consecutive daily declines. No specific news was identified.

Confronto tra pari

Modifica del prezzo

Ionis Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

66.32% in crescita

Previsioni per 12 mesi

Media 90.13 USD  66.32%

Alto 115 USD

Basso 68 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ionis Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

18 ratings

15

Acquista

3

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat